EMTN Programme: publication of a Base Prospectus

Reckitt Benckiser Group PLC
03 June 2024
 

3 June 2024

Reckitt Benckiser Group PLC

EMTN Programme: publication of Base Prospectus

Reckitt Benckiser Group plc (the "Company") today announces that the base prospectus for the £10,000,000,000 Euro Medium Term Note ("EMTN") Programme of Reckitt Benckiser Treasury Services plc, guaranteed by the Company, has been published (the "Base Prospectus").

A copy of the Base Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at and can be downloaded from:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism 

and

https://reckitt.com/investors/your-shareholding/debt-investors/

For further information:

Richard Joyce             +44 (0)7807 418516
Investor Relations

Catheryn O'Rourke                  +44 (0) 1753 217 800
Company Secretary

About Reckitt:

Reckitt* exists to protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. We believe that access to the highestquality hygiene, wellness and nourishment is a right, not a privilege.

Reckitt is the company behind some of the world's most recognisable and trusted consumer brands in hygiene, health and nutrition, including Air Wick, Biofreeze, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, Woolite and more.

Every day, more than 30 million Reckitt products are bought globally. We always put consumers and people first, seek out new opportunities, strive for excellence in all that we do and build shared success with all our partners. We aim to do the right thing, always.

We are a diverse global team of c. 40,000 colleagues. We draw on our collective energy to meet our ambitions of purpose led brands, a healthier planet and a fairer society. Find out more, or get in touch with us at www.reckitt.com.

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

This announcement does not constitute or form part of an offer to sell or the solicitation of an offer to subscribe for or otherwise acquire any securities.

The securities referred to herein and the guarantee thereof have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any State or other jurisdiction of the United States, and are subject to Unites States tax law requirements. Subject to certain exceptions, the securities referred to herein may not be offered, sold or delivered in the United States (as defined in Regulation S under the Securities Act) or to, or for the account or benefit of, U.S. persons (as defined in the U.S. Internal Revenue Code of 1986, as amended, and regulations thereunder). The Base Prospectus may not be accessed from, or transmitted in or into, the United States. Accordingly, these securities may not be offered, sold or delivered in the United States.

Please note that the information contained in the Base Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Prospectus is not addressed. Prior to relying on the information contained in the Base Prospectus, you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirements.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings